SLC5A2 and diabetic neuropathy: Taking the limited efficacy of existing treatments into account, these potential protective effects are particularly salient in the context of diabetic neuropathy’s complexity and, by directly or indirectly reducing oxidative stress and influencing pathways that underlie nerve damage, SGLT-2 inhibitors could herald a paradigm shift in the management of this challenging complication [2,6].